Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Common Equity (2016 - 2025)

Historic Common Equity for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $505.8 million.

  • Ani Pharmaceuticals' Common Equity fell 99.47% to $505.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.8 million, marking a year-over-year decrease of 99.47%. This contributed to the annual value of $403.7 million for FY2024, which is 2147.88% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Common Equity stood at $505.8 million, which was down 99.47% from $436.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Common Equity ranged from a high of $514.1 million in Q4 2023 and a low of $191.4 million during Q3 2021
  • In the last 5 years, Ani Pharmaceuticals' Common Equity had a median value of $403.9 million in 2022 and averaged $389.3 million.
  • In the last 5 years, Ani Pharmaceuticals' Common Equity surged by 10866.76% in 2022 and then crashed by 2147.88% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Common Equity (Quarter) stood at $387.8 million in 2021, then increased by 4.14% to $403.9 million in 2022, then rose by 27.28% to $514.1 million in 2023, then decreased by 21.48% to $403.7 million in 2024, then increased by 25.3% to $505.8 million in 2025.
  • Its Common Equity was $505.8 million in Q3 2025, compared to $436.8 million in Q2 2025 and $418.6 million in Q1 2025.